Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27842796 | 0.85 | CYP2C9 (0.48) | KDM1AHDAC1CYP2C9CYP2C19HDAC6 | |
| SCHEMBL2262047 | 0.82 | KDM1A (0.59) | KDM1AHDAC1CYP2C9CYP2C19HDAC6 | |
| SCHEMBL31418164 | 0.81 | CYP2C9 (0.51) | HDAC1CYP2C9CYP2C19HDAC6CYP2A6 | |
| SCHEMBL7086255 | 0.79 | CYP2C9 (0.55) | CYP2C9CYP2C19SMN1; SMN2CTSAIMPDH2 | |
| SCHEMBL14691464 | 0.77 | CYP2C9 (0.49) | CYP2C9CYP2C19SMN1; SMN2CTSAALDH1A1 | |
| SCHEMBL25234831 | 0.75 | CYP2C9 (0.54) | CYP2C9CYP2C19CYP2A6SMN1; SMN2CTSA | |
| SCHEMBL15830643 | 0.75 | CYP2C9 (0.54) | CYP2C9CYP2C19SMN1; SMN2IMPDH2DPP4 | |
| SCHEMBL12812860 | 0.75 | CYP2C9 (0.54) | CYP2C9CYP2C19SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL5372083 | 0.75 | CYP2C9 (0.65) | CYP2C9CYP2C19SMN1; SMN2CTSALMNA | |
| SCHEMBL277284 | 0.75 | CYP2C19 (0.86) | CYP2C9CYP2C19SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2860178-B1 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2860178-A2 | P2X3 receptor antagonists for treatment of pain | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | disclosed |
| US-8598209-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| EP-2358371-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010051188-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | KDM1A 3570/4885HDAC1 3459/4885CYP2C9 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.